𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan

✍ Scribed by Yasuhito Nannya; Hiromitsu Yokota; Yumiko Sato; Go Yamamoto; Takashi Asai; Motoshi Ichikawa; Takuro Watanabe; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Shigeru Chiba; Yutaka Yatomi; Mineo Kurokawa

Book ID
107618562
Publisher
Carden Jennings Publishing
Year
2008
Tongue
English
Weight
255 KB
Volume
88
Category
Article
ISSN
0925-5710

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prediction of initial cytogenetic respon
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
✍ Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Ke πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 76 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Obtaining a major (Philadelphia chromosome [Ph] of < 35%) or a complete cytogenetic response (Ph of 0%) has been associated with excellent long‐term survival. Cytogenetic response may continue to improve with therapy. Because early allogeneic stem cell transplantation (SC

Chronic myelogenous leukemia in T cell l
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
✍ Ehab Atallah; Moshe Talpaz; Susan O'brien; Mary Beth Rios; Jie Qiang Guo; Ralph πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 57 KB

## Abstract ## BACKGROUND A T cell lymphoid blastic phase of chronic myelogenous leukemia (CML) is a rare occurrence, with only a few reported cases worldwide. Standard therapy for such patients is undetermined. Imatinib mesylate, a Bcr‐Abl tyrosine kinase inhibitor, has shown activity in CML. ##